Investment Rating - The report maintains a rating of "Outperform" for the company [6][9]. Core Insights - The company reported a revenue of 227 million yuan for the first three quarters of 2025, representing a year-on-year increase of 23.5%. The net profit attributable to the parent company was 18 million yuan, marking a return to profitability [6]. - In Q3 2025, the company achieved a revenue of 91 million yuan, up 9.8% year-on-year, with a net profit of 13 million yuan, reflecting a 35.3% increase [6]. - The report highlights that the company's revenue growth is driven by the high demand for its chromatography and spectroscopy series, despite a high base effect from the previous year [9]. - The gross margin for Q3 2025 was 63.0%, slightly down by 1.2 percentage points year-on-year, attributed to a higher proportion of lower-margin products [9]. - The report emphasizes the growth potential in the domestic high-end scientific instrument market, supported by government policies and increasing research and testing demands [9]. - The company is expected to benefit from a clear long-term growth momentum, with strong product launches and a broad customer base [9]. Financial Data and Profit Forecast - The total revenue forecast for 2025 is 378 million yuan, with a projected growth rate of 21.9% [8]. - The net profit attributable to the parent company is expected to reach 45 million yuan in 2025, with a significant year-on-year growth of 246.6% [8]. - The report projects a steady increase in earnings per share, estimating 0.53 yuan per share for 2025 [8]. - The company's price-to-earnings ratio is forecasted to be 51 for 2025, decreasing to 31 by 2027 [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has shown continuous high performance in its earnings, with the recent launch of a new near-infrared spectrometer expected to drive additional revenue growth [5] - The company reported a revenue of 227 million yuan for Q1-Q3 2025, representing a year-on-year increase of 24%, and a net profit attributable to shareholders of 18.11 million yuan, marking a turnaround from losses [7] - The company is focusing on expanding its international distribution channels and participating in significant exhibitions to accelerate overseas growth [7] Financial Performance Summary - Revenue projections for the company are as follows: 341 million yuan in 2023, 310 million yuan in 2024, 370 million yuan in 2025E, 437 million yuan in 2026E, and 526 million yuan in 2027E [6] - The company achieved a net profit of 12.63 million yuan in Q3 2025, which is a 35% increase year-on-year and a 111% increase quarter-on-quarter [7] - The company’s R&D expenses for Q1-Q3 2025 were 38.71 million yuan, with a R&D expense ratio of 17%, indicating a strong focus on high-end instrument localization [7] Earnings Forecast and Valuation - The forecasted net profits for the company from 2025 to 2027 are 50 million yuan, 63 million yuan, and 80 million yuan, respectively, corresponding to price-to-earnings ratios of 46.0, 36.5, and 28.8 times [8] - The company has been actively repurchasing shares, completing a buyback plan in October 2025, which accounted for 4.1% of the total share capital [7]